# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://www.fda.gov/medical-devices/medical-device-recalls/hologic-inc-recalls-biozorb-marker-due-complications-implanted-devices
https://www.fda.gov/medical-devices/medical-device-recalls/hologic-inc-recalls-biozorb-marker-due-complications-implanted-devices
Argus Research analyst David Toung maintains Hologic (NASDAQ:HOLX) with a Buy and raises the price target from $89 to $95.
JP Morgan analyst Casey Woodring maintains Hologic (NASDAQ:HOLX) with a Overweight and raises the price target from $85 to $91.
Needham analyst Mike Matson reiterates Hologic (NASDAQ:HOLX) with a Buy and maintains $90 price target.
Hologic (NASDAQ:HOLX) reported quarterly Adj earnings of $1.03 per share which beat the analyst consensus estimate of $0.98 by ...